CDKN2A and type 2 diabetes mellitus: Furthermore, on the basis of large-scale cohorts from the UK Biobank, we confirmed that the SRI-based model is superior to models based on other driver genes, such as KRAS, in differentiating PCAND from T2DM and that the combination of SRI, KRAS, and CDKN2A with a clinical model can further increase the efficiency.